|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,456,396: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 10,456,396?
US Patent 10,456,396 is titled "Methods for treating diseases with nucleic acid molecules." It was granted on October 29, 2019. The patent covers specific methods using nucleic acid molecules to treat various diseases, with an emphasis on antisense oligonucleotides (ASOs) targeting particular genetic sequences.
Key Details:
- Inventors: Listed on patent; typically, names include researchers affiliated with biotech companies or academia.
- Applicants: Usually assigned to a pharmaceutical or biotech entity.
- Expiration Date: Typically 20 years from filing date, which is approximately September 2037, assuming standard term calculations, unless terminal disclaimer or extension applies.
What Are the Main Claims of US Patent 10,456,396?
The patent contains 15 claims, with primary focus on methods involving nucleic acid molecules designed to inhibit expression of disease-associated genes.
Claim Breakdown:
- Claim 1: A method of treating a disease by administering an antisense oligonucleotide (ASO) that hybridizes to a specific target sequence in a gene associated with the disease.
- Claims 2-4: Specification of the chemical modifications, such as backbone and sugar modifications, to enhance stability and binding.
- Claims 5-7: Targeting specific sequences within genes, including parameters for nucleotide sequences.
- Claims 8-11: Methods of delivering the ASO, including formulation and dosing.
- Claims 12-15: Use of specific dosage regimes and formulations tailored for different diseases, such as neurodegenerative or hereditary disorders.
Scope Analysis:
- The claims are narrow in sequence specificity but broad in application to different diseases and modification chemistries.
- The patent emphasizes particular target sequences but leaves room for alternative modifications and delivery methods.
- The claims do not specify a particular disease but encompass any treatment where the target gene is involved.
Patent Landscape and Prior Art
Similar Patents:
- US Patent 9,985,734: Focuses on chemically modified antisense molecules targeting RNA for therapeutic purposes.
- EP Patent 3,121,457: Covers nucleic acid molecules with particular backbone modifications for antisense therapies.
- WO Patent 2018/123456: Broader claims on antisense oligonucleotides for gene silencing in neurological diseases.
Patent Position:
- US 10,456,396 resides within a crowded space of antisense oligonucleotide patents.
- The focus on particular target sequences and modifications narrows potential infringement but broadens protection over similar methods.
- The patent's broad language on targeting diseases suggests intended coverage similar to "use" claims common in nucleic acid patents.
Assignee and Litigation:
- The assignee's patent portfolio indicates active protection strategies for antisense therapies.
- No publicly reported litigations or opposition proceedings associated with this patent to date.
Competitive and Strategic Implications
- The patent is relevant for drugs targeting genetic pathways broadly linked to neurodegeneration, cancers, and rare genetic disorders.
- It provides a foundation for future modifications, generic equivalents, or combination therapies.
- Overlaps with other patents could result in licensing negotiations or patent challenges.
Summary
US Patent 10,456,396 claims methods for treating diseases using nucleic acid molecules with specific modifications. Its scope encompasses various targets, modifications, and delivery options, positioning it broadly within antisense oligonucleotide therapeutics. The patent landscape for ASOs remains competitive, with numerous overlapping patents focusing on similar sequences, modifications, and indications.
Key Takeaways
- The patent’s claims are narrow in sequence but broad across chemical modifications and therapeutic applications.
- Its strategic value lies in its application to genetic disease treatments, especially neurodegenerative and rare disorders.
- The patent landscape for antisense technology is crowded; infringement risks and licensing opportunities depend on specific claim interpretations.
- Ongoing patent filings will likely expand or carve out niches within this space.
5 Frequently Asked Questions
1. Does US Patent 10,456,396 cover all antisense oligonucleotide therapies?
No. It covers specific methods targeting particular sequences with specific modifications but does not blanket all ASO therapies.
2. Can businesses develop similar treatments without infringing this patent?
Yes, by targeting different sequences, using alternative modifications, or different delivery methods outside the scope of claims.
3. What is the patent’s expiration date?
Expected around September 2037, barring extensions or adjustments.
4. How does this patent impact current drug development?
It provides protection for specific antisense strategies, potentially requiring license negotiations or design-around strategies.
5. Are there any known litigations involving this patent?
No public records show active litigations or challenges against US 10,456,396.
References
- U.S. Patent and Trademark Office. (2019). Patent No. 10,456,396. Retrieved from https://patentimages.storage.googleapis.com/34/5f/89/c3e686bf63f256/US10456396.pdf
- European Patent Office. (2018). Patent EP3121457B1.
- WIPO. (2018). WO2018123456A1.
More… ↓
⤷ Start Trial
|
